Response to the Letter to the Editor by Lockley et al. commenting on ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’

We have read with interest the letter to you from Dr Lockley and colleagues [1] published in response to our manuscript entitled ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’ that supports surveillance rather than adjuvant chemotherapy in stage I immature teratomas (ITs). This paper was based on the evaluation of the o utcomes of 108 patients with pure ITs, as a result of an international collaboration [2].

Source: European Journal of Cancer - June 8, 2021 Category: Cancer & Oncology Authors: Alice Bergamini, Naveed Sarwar, Gabriella Ferrandina, Giovanna Scarfone, Dee Short, Xianne Aguiar, Cristina Camnasio, Baljeet Kaur, Philip M. Savage, Gennaro Cormio, Adrian Lim, Sandro Pignata, Giorgia Mangili, Michael J. Seckl Tags: Author ’s reply Source Type: research